Hemochromatosis and Heart Involvement
Open Access
- 27 November 2024
- journal article
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 14 (6) , 442-456
Abstract
Hemochromatosis is a life-threatening condition if left untreated, that is caused by excess iron in the body. It can be primary (hereditary) hemochromatosis, resulting from genes mutations, and secondary (acquired) as a result of excessive intake of iron from food or drugs, liver diseases or repeated blood transfusions. Deposition of excess iron in parenchymal tissues leads to cellular dysfunction and clinical manifestations of the disease. The liver, pancreas, joints, skin, pituitary gland and heart are most often affected. Cardiac hemochromatosis is an important and potentially preventable cause of heart failure. Initially, diastolic dysfunction and arrhythmias develop, at later stages a picture of dilated cardiomyopathy can appear. Signs of heart damage in hemochromatosis can be detected using complex 2D and Doppler echocardiography, cardiac MRI with T2* relaxation time measurement and other diagnostic methods. Genetic testing is the gold standard for diagnosing hemochromatosis and should be performed after secondary causes of iron overload have been excluded. The basis of therapy is therapeutic phlebotomy and iron chelation. Median survival is less than a year in untreated patients with severe heart failure caused by hemochromatosis. However, with early and aggressive treatment, survival approaches that of patients with heart failure of other etiologies.Keywords
This publication has 44 references indexed in Scilit:
- Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the LiverHepatology International, 2023
- Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic MalignancyJAMA, 2020
- Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFEClinical Gastroenterology and Hepatology, 2020
- Worse Outcomes of Patients With HFE Hemochromatosis With Persistent Increases in Transferrin Saturation During Maintenance TherapyClinical Gastroenterology and Hepatology, 2017
- DXA: Technical aspects and applicationEuropean Journal of Radiology, 2016
- HaemochromatosisThe Lancet, 2016
- Course of iron parameters in HFE‐hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomyJournal of Clinical Apheresis, 2016
- Percutaneous excretion of iron and ferritin (through Al-hijamah) as a novel treatment for iron overload in beta-thalassemia major, hemochromatosis and sideroblastic anemiaMedical Hypotheses, 2014
- HFE-Related Hemochromatosis: An Update for the RheumatologistCurrent Rheumatology Reports, 2013
- Cardiac transplantation in patients with iron overload cardiomyopathyThe Journal of Heart and Lung Transplantation, 2005